Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Consolidated Net Income (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Consolidated Net Income data on record, last reported at -$18.9 million in Q1 2026.

  • On a quarterly basis, Consolidated Net Income fell 7.0% to -$18.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$76.1 million, a 14824.71% decrease, with the full-year FY2025 number at -$74.9 million, down 669.97% from a year prior.
  • Consolidated Net Income reached -$18.9 million in Q1 2026 per FULC's latest filing, up from -$20.3 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for FULC hit a ceiling of $55.4 million in Q2 2024 and a floor of -$34.1 million in Q2 2022.
  • A 5-year average of -$18.3 million and a median of -$23.7 million in 2022 define the central range for Consolidated Net Income.
  • Peak YoY movement for Consolidated Net Income: surged 332.98% in 2024, then plummeted 131.22% in 2025.
  • Tracing FULC's Consolidated Net Income over 5 years: stood at -$26.1 million in 2022, then increased by 5.28% to -$24.8 million in 2023, then skyrocketed by 33.07% to -$16.6 million in 2024, then fell by 22.73% to -$20.3 million in 2025, then increased by 7.1% to -$18.9 million in 2026.
  • Business Quant data shows Consolidated Net Income for FULC at -$18.9 million in Q1 2026, -$20.3 million in Q4 2025, and -$19.6 million in Q3 2025.